International Journal of Molecular Sciences · 2021 · 17 citations · 22 references
PharmacyBiochemistryPharmacologyDrug DiscoveryEnzymologyMolecular OncologyAssay DevelopmentCoenzyme ChemistryEnzyme InhibitionEnzyme ScreeningMolecular ScreeningSmall-molecule ScreeningAssay SpecificityFluorescence-based AssaysFluorescence-based ScreeningFluorescence-based SensingFluorescent LabelsFluorescent ProbesHistone AcetyltransferasesInhibitor Screening
-terminal acetyltransferase D (NatD) is one of the most specific NAT with only histone H4 and H2A proteins as the known substrates. Dysregulation of NatD has been implicated in colorectal and lung cancer progression, implying its therapeutic potential in cancers. However, there is no reported inhibitor for NatD yet. To facilitate the discovery of small-molecule NatD inhibitors, we report the development of a fluorescence-based acetyltransferase assay in 384-well high-throughput screening (HTS) format through monitoring the formation of coenzyme A. The fluorescent signal is generated from the adduct in the reaction between coenzyme A and fluorescent probe ThioGlo4. The assay exhibited a Z'-factor of 0.77 and a coefficient of variation of 6%, indicating it is a robust assay for HTS. A pilot screen of 1280 pharmacologically active compounds and subsequent validation identified two hits, confirming the application of this fluorescence assay in HTS.
22
George L. Ellman · Archives of Biochemistry and Biophysics · 1959 · 26.2K citations
Thomas Arnesen, Petra Van Damme, Bogdan Polevoda et al. · Proceedings of the National Academy of Sciences · 2009 · 560 citations